IGF-1 LR3 Research: Myocyte Cell Models and Endocrine Pathway Studies
Peptide Structure and Receptor Pharmacology
IGF-1 LR3 represents a modified analog of insulin-like growth factor-1, engineered through the substitution of glutamic acid for arginine at position 3 and the addition of a 13-amino acid N-terminal extension. This structural modification significantly alters the compound's binding affinity profile compared to native IGF-1. In vitro receptor pharmacology studies demonstrate that IGF-1 LR3 exhibits reduced binding affinity for insulin-like growth factor binding proteins (IGFBPs) while maintaining substantial affinity for the IGF-1 receptor (IGF-1R).
Cell-based radioligand binding assays reveal that IGF-1 LR3 displays approximately 2-3 fold lower binding affinity for the IGF-1 receptor compared to native IGF-1, with dissociation constant (Kd) values typically ranging from 1-3 nM in various cell model systems. The extended half-life characteristics observed in cell culture media result from dramatically reduced IGFBP binding, with binding affinity decreased by approximately 100-1000 fold compared to wild-type IGF-1.
Myocyte Cell Model Systems
Primary Myocyte Cultures
Primary myocyte cell cultures serve as fundamental research models for investigating IGF-1 LR3 receptor pharmacology. C2C12 myoblast cell lines differentiated into myotubes provide standardized in vitro systems for examining receptor activation kinetics and downstream signalling cascades. These cell models express high densities of IGF-1 receptors, making them particularly suitable for binding affinity studies and functional receptor assays.
Isolated primary skeletal muscle cells from various species demonstrate consistent receptor expression patterns and signalling pathway responses to IGF-1 LR3 exposure. These primary cell cultures maintain physiologically relevant receptor densities and co-expression of associated signalling proteins, providing robust experimental systems for mechanistic studies.
Cell Line Characterization
Immortalized myoblast cell lines, including L6 and Sol8 cell models, offer reproducible experimental platforms for IGF-1 LR3 research. These cell systems express functional IGF-1 receptors and associated downstream signalling components, enabling comprehensive receptor pharmacology investigations. Cell viability assays and receptor expression profiling confirm the suitability of these model systems for studying IGF-1 LR3 binding kinetics and functional responses.
Endocrine Signalling Pathway Mechanisms
IGF-1 Receptor Activation
IGF-1 LR3 binding to the IGF-1 receptor initiates autophosphorylation of tyrosine residues within the receptor's intracellular domain. This phosphorylation event creates docking sites for insulin receptor substrate (IRS) proteins, particularly IRS-1 and IRS-2. Phosphorylation kinetics studies using cell-based assays demonstrate that IGF-1 LR3 activates receptor autophosphorylation with similar temporal characteristics to native IGF-1, despite the reduced binding affinity.
PI3K/Akt Pathway Activation
Downstream of IRS protein recruitment, IGF-1 LR3 stimulates phosphatidylinositol 3-kinase (PI3K) activation through SH2 domain interactions. Cell-based enzyme kinetic assays reveal that PI3K activation leads to enhanced phosphatidylinositol (3,4,5)-trisphosphate (PIP3) production, subsequently recruiting and activating protein kinase B (Akt/PKB). Western blot analyses of phosphorylated Akt at Ser473 and Thr308 residues provide quantitative measures of pathway activation in response to IGF-1 LR3 exposure.
mTOR Signalling Complex Engagement
Activated Akt phosphorylates multiple downstream targets, including mammalian target of rapamycin complex 1 (mTORC1). In vitro assays measuring phosphorylation of ribosomal protein S6 kinase 1 (S6K1) and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) demonstrate robust mTORC1 activation following IGF-1 LR3 treatment in myocyte cell models. These phosphorylation events regulate protein synthesis machinery and represent key mechanistic endpoints in cell-based functional assays.
Binding Kinetics and Enzyme Activity
Saturation binding experiments using radiolabeled IGF-1 LR3 in myocyte cell preparations reveal specific binding characteristics and receptor occupancy profiles. Competition binding assays with unlabeled IGF-1 and insulin demonstrate the selectivity profile of IGF-1 LR3 for IGF-1 receptors versus insulin receptors. Kinetic binding studies measuring association (kon) and dissociation (koff) rate constants provide comprehensive pharmacological profiles for this modified peptide analog.
Research Summary
IGF-1 LR3 demonstrates distinct receptor pharmacology characteristics in myocyte cell model systems, exhibiting reduced IGFBP binding while maintaining functional IGF-1 receptor activation. The compound engages canonical endocrine signalling pathways including PI3K/Akt and mTOR cascades with kinetics comparable to native IGF-1. These in vitro findings establish IGF-1 LR3 as a valuable research tool for investigating insulin-like growth factor receptor pharmacology and associated signalling mechanisms in controlled cell culture environments.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
Hexarelin
TB-500
Epithalon
Ipamorelin
Tirzepatide
CJC-1295 DAC
PT-141
Semaglutide
Selank
BPC-157
Sermorelin
Melanotan 2
IGF LR3
Tesamorelin
AICAR
IGF-DES
GHRP 2
Albuterol
Tamoxifen
Letrozole
Clomiphene
Tadalafil
Clenbuterol
Anastrozole
Finasteride
Exemestane
Sildenafil
Yohimbine
Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows
Already a customer? Sign In
Create Account
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
Sarms
Stacks
Research Liquids
Albuterol 5MG/ML | 30ML with dropper
Anastrozole 1.5MG/ML | 30ML with dropper
Clomiphene 50MG/ML | 30ML with dropper
Finasteride 5MG/ML | 30ML with dropper
Letrozole 3.5 MG/ML | 30ML with dropper
LiquiCia 30MG/ML | 30ML with dropper
LiquiCia T50 50MG/ML | 30ML with dropper
LiquiClen 200MCG/ML | 30ML with dropper
Liquistane / Exemestane 25MG/ML | 30ML with dropper
LiquiTamo 20MG/ML | 30ML with dropper
LiquiVia 25MG/ML | 30 ML with dropper
T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper
Toremifene Citrate 60MG/ML | 30ML with dropper
Yohimbine HCL 10MG/ML | 30ML with dropper
Research Peptides
Aicar 50MG
BPC-157 + TB-500 Blend 2mg ea/ 4MG
BPC-157 5MG
CJC-1295 + DAC 2MG
CJC-1295 | No DAC 2MG
Epithalon 10MG
Frag Premium 176-191 5MG
GHK-CU Copper Peptide 50MG
GHRP-2 5MG
GHRP-6 5MG
Hexarelin 5MG
IGF-1 DES 1MG
IGF-1 LR3 1MG
Ipamorelin 5MG
Melanotan 2 10MG
NAD+ 500MG
PT-141 / Bremelanotide 10MG
GLP-1/GIP/GCG (RT)
Selank 5MG
GLP1 (SM)
Sermorelin 5MG
TB-500 5MG
GIP/GLP-1 (TZ)
PDE5 Inhibitors
GLP-1
Diluents
Bacteriostatic Water 10ML